Operose Advisors’s Whitehawk Therapeutics WHWK Stock Holding History

Operose Advisors’s Portfolio WHWK Stock Details WHWK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-500	Closed	-$2.42K	–	744
2023 Q3	$2.42K	Buy	+500	New	+$2.91K	﹤0.01%	697

Other funds holding WHWK

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Operose Advisors's WHWK Position: Q4 2023 in Review

Operose Advisors sold out of Whitehawk Therapeutics (WHWK) in Q4 2023, closing a stake of 500 shares — an estimated $2.42K sold.

Operose Advisors first reported a position in WHWK in Q3 2023 and held it in 1 quarter. The position peaked at $2.42K in Q3 2023. 65 funds tracked by Wall St. Rank hold WHWK as of Q4 2023.

Operose Advisors reported no remaining Whitehawk Therapeutics position as of Q4 2023 after selling out during the quarter.
Operose Advisors sold 500 Whitehawk Therapeutics shares in Q4 2023, an estimated $2.42K.
Operose Advisors first reported a position in Whitehawk Therapeutics in Q3 2023 and held it in 1 quarter.
Operose Advisors's Whitehawk Therapeutics position peaked at $2.42K in Q3 2023.
65 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q4 2023.

Based on Operose Advisors's 13F filing for Q4 2023, filed 12 Feb 2024.